Compared side by side

Semaglutide vs dulaglutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are weekly GLP-1 receptor agonists, built differently: semaglutide mimics the gut hormone GLP-1 and lasts about a week, and dulaglutide is a fusion protein, two GLP-1 analogue chains joined to an antibody fragment, that lasts about 5 days. Semaglutide is FDA-approved for type 2 diabetes and weight management, as Ozempic and Wegovy; dulaglutide (Trulicity) is approved for type 2 diabetes and to lower cardiovascular events, and not for weight management. Semaglutide averaged about 15% weight loss at 68 weeks in its main trial, while dulaglutide’s effect on weight was about 1 to 5 kg in its diabetes trials.

Side by side

ComparedSemaglutideDulaglutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asOzempic, WegovyTrulicity, LY2189265, Dula
What it isA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.A weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens.
How it worksGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.GLP-1 receptor agonist made as a fusion protein: two GLP-1 analogue chains, 90% the same as human GLP-1, joined to the Fc fragment of a modified IgG4 antibody (about 63 kDa). It releases insulin when glucose is high, lowers glucagon and slows stomach emptying. Its large Fc-fusion design slows its clearance, to a half-life of about 5 days, which makes it a weekly shot. FDA-approved in 2014 for type 2 diabetes (adults, and children 10 and older) and to lower major cardiovascular events in adults with type 2 diabetes and heart disease or its risk factors; it is not approved for weight management.
Commonly reportedThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.Steadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it.
Studied rangeFDA label: 0.25–2.4 mg, starting dose 0.25 mg.FDA label: 0.75–4.5 mg, starting dose 0.75 mg.
How oftenWeekly SubQWeekly
Half-life~1 week (FDA label)~5 days (FDA label)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.FDA-approved for ongoing use; its heart-outcomes trial followed people for a median of 5.4 years. The 3 and 4.5 mg steps are optional, for more glucose control.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis riskNausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide or dulaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Semaglutide

  • Day 1–28 · 0.25 mg Gut is adapting
  • Day 29–56 · 0.5 mg Appetite shifts are real now
  • Day 57–112 · 1 mg Clinically useful weight loss kicks in
  • Day 113–140 · 1.7 mg Max submaximal step
  • Day 141–364 · 2.4 mg Full dose — the working dose
  • Day 365+ Plateau territory — new baseline

Every card for semaglutide, with its sources

Dulaglutide

  • Day 1–28 · 0.75 mg The 0.75 mg start
  • Day 29–364 · 1.5 mg 1.5 mg, the dose of its heart trial
  • Day 57–364 · 3 mg 3 mg, a step for more glucose control
  • Day 85–364 · 4.5 mg 4.5 mg, the top dose
  • Day 365+ A long-term medicine, not a course

Every card for dulaglutide, with its sources

Questions people ask

How long do semaglutide and dulaglutide last?

The half-life of semaglutide is ~1 week (FDA label). The half-life of dulaglutide is ~5 days (FDA label).

How often are semaglutide and dulaglutide taken?

Semaglutide: weekly SubQ. Route: SubQ injection. Dulaglutide: weekly. Route: SubQ injection.

How are semaglutide and dulaglutide dosed in research?

The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The FDA label range for dulaglutide is 0.75–4.5 mg, with a 0.75 mg starting dose.

What are the common side effects of semaglutide and dulaglutide?

For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For dulaglutide: nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue.

Each one in full

Track it in the app

PepVault for iPhone

Taking semaglutide or dulaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo